Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

BA-BE Studies: SOP for Chromatographic Peak Integration Rules – V 2.0

Posted on By

BA-BE Studies: SOP for Chromatographic Peak Integration Rules – V 2.0

Standard Operating Procedure for Chromatographic Peak Integration Rules in BA/BE Bioanalytical Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/166/2025
Supersedes SOP/BA-BE/166/2022
Page No. Page 1 of 12
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define uniform and validated rules for chromatographic peak integration in bioanalytical assays conducted using LC-MS/MS, to ensure consistency and regulatory compliance across BA/BE studies.

2. Scope

This SOP applies to all chromatographic runs generated during bioanalysis of pharmacokinetic samples in BA/BE studies using LC-MS/MS systems operated by bioanalytical scientists.

3. Responsibilities

  • Analyst: Performs chromatographic integration using validated parameters and
flags abnormalities.
  • Reviewer (QA/Scientific): Reviews integration accuracy and compliance with established rules.
  • Lab Supervisor: Approves manual integrations and verifies method adherence.
  • 4. Accountability

    The Bioanalytical Lab Head is accountable for ensuring consistent application of integration rules and documentation of any deviations.

    5. Procedure

    5.1 Integration Software Settings

    1. Use validated integration methods (e.g., centroid, height-based, area-based) pre-set in software (Analyst™, Empower™, MassLynx™, etc.).
    2. Ensure peak width, threshold, and smoothing settings match parameters established in bioanalytical method validation.
    3. Do not alter default integration parameters unless justified and documented.

    5.2 Peak Selection Rules

    1. Accept peaks that:
      • Match expected retention time ±2%
      • Have S/N ratio ≥ 10 at LLOQ
      • Do not show peak fronting or tailing beyond symmetry factor limits (0.8–1.5)
    2. Flag peaks with co-elution, doublets, or inconsistent baseline for scientific review.

    5.3 Manual Integration Policy

    1. Manual integration may be applied when:
      • Baseline noise causes incorrect automatic peak delineation
      • Split peaks need unification into a single quantifiable peak
      • Software fails to detect known peak above threshold
    2. Document every manual integration in Annexure-1: Manual Integration Log and include justification.

    5.4 Peak Area and Retention Time Validation

    1. Cross-check peak area and retention time (RT) against reference injections of standards and QCs.
    2. Evaluate any unexpected shift in RT (greater than ±2%) or change in area (RSD > 5% for replicates).

    5.5 Peak Shape and Chromatogram Quality

    1. Acceptable peak shapes:
      • Gaussian or symmetrical
      • Symmetry factor between 0.8 and 1.5
    2. Reject results with:
      • Baseline drift or instability
      • Negative peaks, spike noise, or ghost peaks

    5.6 Data Integrity and Audit Trail

    1. Ensure that software audit trails are enabled and capture:
      • Date/time of integration
      • Username and reason for manual edits
      • Chromatogram overlay before and after edits
    2. QA must review audit trail for all manual integrations prior to batch approval.

    5.7 Reviewer Checks

    1. Scientific reviewer must:
      • Verify peak integration accuracy for at least 10% of chromatograms
      • Cross-validate LLOQ, ULOQ, and IS peaks across calibration curves and unknown samples
      • Approve batch only after resolving discrepancies

    6. Abbreviations

    • BA/BE: Bioavailability/Bioequivalence
    • LC-MS/MS: Liquid Chromatography-Tandem Mass Spectrometry
    • S/N: Signal-to-Noise Ratio
    • IS: Internal Standard
    • RT: Retention Time

    7. Documents

    1. Manual Integration Log – Annexure-1

    8. References

    • ICH M10: Bioanalytical Method Validation
    • FDA and EMA Bioanalytical Guidelines
    • Vendor User Manuals for Chromatographic Software

    9. SOP Version

    Version: 2.0

    10. Approval Section

    Prepared By Checked By Approved By
    Signature
    Date
    Name
    Designation
    Department

    11. Annexures

    Annexure-1: Manual Integration Log

    Date Analyst Sample ID Integration Type Reason for Manual Integration Reviewer Remarks
    16/04/2025 Rajesh Kumar BE012-TP5 Area-based Split peak due to baseline noise Accepted

    Revision History:

    Revision Date Revision No. Details Reason Approved By
    01/01/2022 1.0 Initial release New SOP QA Head
    17/04/2025 2.0 Updated with audit trail checks and reviewer roles Data Integrity Compliance QA Head
    See also  BA-BE Studies: SOP for Clinical Documentation of Adverse Events - V 2.0
    BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

    Post navigation

    Previous Post: Creams: SOP for Performing Emulsion Stability Tests during Processing – V 2.0
    Next Post: Gel Manufacturing: SOP for Cleaning Gel Mixing Vessels – V 2.0

    Standard Operating Procedures V 1.0

    • Aerosols
    • Analytical Method Development
    • Bioequivalence Bioavailability Study
    • Capsule Formulation
    • Clinical Studies
    • Creams
    • Data Integrity
    • Dental Dosage Forms
    • Drug Discovery
    • Environment, Health and Safety
    • Formulation Development
    • Gels
    • Good Distribution Practice
    • Good Warehousing Practices
    • In-Process Control
    • Injectables
    • Liquid Orals
    • Liposome and Emulsion Formulations
    • Lotions
    • Lyophilized Products
    • Maintenance Dept.
    • Medical Devices
    • Metered-Dose Inhaler
    • Microbiology Testing
    • Nanoparticle Formulation
    • Nasal Spray Formulations
    • Nebulizers
    • Ocular (Eye) Dosage Forms
    • Ointments
    • Otic (Ear) Dosage Forms
    • Pharmacovigilance
    • Powder & Granules
    • Purchase Departments
    • Quality Assurance
    • Quality Control
    • Raw Material Stores
    • Regulatory Affairs
    • Tablet Manufacturing
    • Rectal Dosage Forms
    • Transdermal Patches
    • Vaginal Dosage Forms
    • Validations and Qualifications

    Read SOPs in your Language:

     - 
    Bengali
     - 
    bn
    English
     - 
    en
    Gujarati
     - 
    gu
    Hindi
     - 
    hi
    Malayalam
     - 
    ml
    Marathi
     - 
    mr
    Punjabi
     - 
    pa
    Tamil
     - 
    ta
    Telugu
     - 
    te

    NEW! Revised SOPs – V 2.0

    • Aerosols V 2.0
    • Analytical Method Development V 2.0
    • API Manufacturing V 2.0
    • BA-BE Studies V 2.0
    • Biosimilars V 2.0
    • Capsules V 2.0
    • Creams V 2.0
    • Elixers V 2.0
    • Gels V 2.0
    • Injectables V 2.0
    • Ointments V 2.0
    • Raw Material Warehouse V 2.0
    • Tablet Manufacturing V2.0

    New Publication: A must for All.

    Copyright © 2025 SOP Guide for Pharma.

    Powered by PressBook WordPress theme

    Go to mobile version